Takeda Pharmaceutical Company Limited (TAK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Jun 25, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TAK SEC filings page.
Takeda Pharmaceutical Company Limited (TAK) reported $30.6B in revenue for fiscal year 2025, up 8.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Takeda Pharmaceutical Company Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Takeda Pharmaceutical Company Limited has an operating margin of 7.5%, meaning the company retains $7 of operating profit per $100 of revenue. This results in a moderate score of 59/100, indicating healthy but not exceptional operating efficiency. This is up from 5.0% the prior year.
Takeda Pharmaceutical Company Limited's revenue grew 8.4% year-over-year to $30.6B, a solid pace of expansion. This earns a growth score of 32/100.
Takeda Pharmaceutical Company Limited has elevated debt relative to equity (D/E of 0.57), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 5/100, reflecting increased financial risk.
Takeda Pharmaceutical Company Limited's current ratio of 1.01 is below the typical benchmark, resulting in a score of 19/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Takeda Pharmaceutical Company Limited converts 18.7% of revenue into free cash flow ($5.7B). This strong cash generation earns a score of 82/100.
Takeda Pharmaceutical Company Limited's ROE of 1.6% shows moderate profitability relative to equity, earning a score of 48/100. This is down from 2.0% the prior year.
Takeda Pharmaceutical Company Limited scores 1.30, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Takeda Pharmaceutical Company Limited passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, Takeda Pharmaceutical Company Limited generates $9.80 in operating cash flow ($7.1B OCF vs $720.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Takeda Pharmaceutical Company Limited earns $2.49 in operating income for every $1 of interest expense ($2.3B vs $916.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Takeda Pharmaceutical Company Limited generated $30.6B in revenue in fiscal year 2025. This represents an increase of 8.4% from the prior year.
Takeda Pharmaceutical Company Limited's EBITDA was $2.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 58.0% from the prior year.
Takeda Pharmaceutical Company Limited reported $720.0M in net income in fiscal year 2025. This represents a decrease of 24.4% from the prior year.
Takeda Pharmaceutical Company Limited earned $0.45 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 25.6% from the prior year.
Cash & Balance Sheet
Takeda Pharmaceutical Company Limited generated $5.7B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 59.7% from the prior year.
Takeda Pharmaceutical Company Limited held $2.6B in cash against $26.5B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Takeda Pharmaceutical Company Limited's gross margin was 65.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.0 percentage points from the prior year.
Takeda Pharmaceutical Company Limited's operating margin was 7.5% in fiscal year 2025, reflecting core business profitability. This is up 2.5 percentage points from the prior year.
Takeda Pharmaceutical Company Limited's net profit margin was 2.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.0 percentage points from the prior year.
Takeda Pharmaceutical Company Limited's ROE was 1.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the prior year.
Capital Allocation
Takeda Pharmaceutical Company Limited invested $4.9B in research and development in fiscal year 2025. This represents an increase of 0.9% from the prior year.
Takeda Pharmaceutical Company Limited spent $346.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 2113.0% from the prior year.
Takeda Pharmaceutical Company Limited invested $1.3B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 15.5% from the prior year.
TAK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.6B+8.4% | $28.2B-7.1% | $30.3B+3.2% | $29.4B+1.7% | $28.9B-5.5% | $30.6B+61.5% | $18.9B+13.7% | $16.7B+7.2% | $15.5B |
| Cost of Revenue | $10.5B+11.7% | $9.4B+0.7% | $9.4B+2.8% | $9.1B+1.4% | $9.0B-11.3% | $10.1B+72.1% | $5.9B+26.1% | $4.7B-6.9% | $5.0B |
| Gross Profit | $20.0B+6.7% | $18.8B-10.5% | $21.0B+3.4% | $20.3B+1.8% | $19.9B-2.7% | $20.5B+56.8% | $13.1B+8.8% | $12.0B+14.0% | $10.5B |
| R&D Expenses | $4.9B+0.9% | $4.8B+1.2% | $4.8B+10.1% | $4.3B+5.1% | $4.1B-10.0% | $4.6B+37.6% | $3.3B+8.6% | $3.1B+9.3% | $2.8B |
| Operating Income | $2.3B+61.4% | $1.4B-61.7% | $3.7B-2.6% | $3.8B-17.6% | $4.6B+393.1% | $933.8M-56.5% | $2.1B-5.7% | $2.3B+62.7% | $1.4B |
| EBITDA | $2.3B+58.0% | $1.5B-60.5% | $3.7B-2.3% | $3.8B-19.3% | $4.7B+235.0% | $1.4B-35.0% | $2.2B-10.5% | $2.4B+68.9% | $1.4B |
| Interest Expense | $916.0M+15.9% | $790.5M-10.3% | $881.2M-12.6% | $1.0B-14.7% | $1.2B-14.7% | $1.4B+218.5% | $435.1M+360.4% | $94.5M+39.3% | $67.9M |
| Income Tax | $446.6Mn/m | -$604.5M-238.2% | $437.3M-26.7% | $596.2Mn/m | -$89.8Mn/m | -$976.9Mn/m | -$67.5M-123.5% | $287.2M+14.9% | $249.8M |
| Net Income | $720.0M-24.4% | $952.7M-60.1% | $2.4B+26.1% | $1.9B-44.3% | $3.4B+726.2% | $411.4M-66.3% | $1.2B-30.6% | $1.8B+70.6% | $1.0B |
| EPS (Basic) | $0.46-25.1% | $0.61-60.4% | $1.54+27.0% | $1.21-44.3% | $2.18+723.7% | $0.26 | $1.27-43.6% | $2.25+70.6% | $1.32 |
| EPS (Diluted) | $0.45-25.6% | $0.60-60.4% | $1.52+26.6% | $1.20-44.4% | $2.16+722.4% | $0.26 | $1.26-43.5% | $2.24+70.4% | $1.31 |
| Diluted Shares (Avg) | 1.61B+1.6% | 1.58B+0.7% | 1.57B-0.5% | 1.58B+0.2% | 1.57B+0.5% | 1.57B | 967M+22.9% | 787M+0.1% | 786M |
Not reported in any period shown, so not listed: SG&A Expenses.
TAK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $95.1B-4.9% | $99.9B-5.0% | $105.1B-3.1% | $108.5B-7.0% | $116.7B-2.1% | $119.2B-4.3% | $124.6B+222.3% | $38.7B | N/A |
| Current Assets | $16.8B-0.6% | $16.9B-6.3% | $18.1B-15.4% | $21.4B-12.9% | $24.5B+6.8% | $23.0B-15.1% | $27.0B+166.2% | $10.2B | N/A |
| Cash & Equivalents | $2.6B-15.1% | $3.0B-24.7% | $4.0B-42.6% | $7.0B-19.9% | $8.7B+47.3% | $5.9B-6.5% | $6.3B+128.7% | $2.8B-3.3% | $2.9B |
| Inventory | $8.1B+1.5% | $8.0B+7.7% | $7.4B+5.8% | $7.0B+3.1% | $6.8B-3.5% | $7.1B-15.0% | $8.3B+314.4% | $2.0B | N/A |
| Accounts Receivable | $4.7B+7.1% | $4.4B-9.6% | $4.9B-14.7% | $5.7B-19.0% | $7.1B+0.6% | $7.0B+5.0% | $6.7B+69.4% | $4.0B | N/A |
| Goodwill | $35.5B-0.7% | $35.8B-0.9% | $36.1B-0.6% | $36.3B-0.5% | $36.5B-2.3% | $37.3B-2.6% | $38.3B+295.3% | $9.7B | N/A |
| Total Liabilities | $48.8B-5.8% | $51.8B-9.5% | $57.3B-7.2% | $61.7B-11.8% | $69.9B-7.1% | $75.3B-3.2% | $77.8B+295.3% | $19.7B | N/A |
| Current Liabilities | $16.7B+9.3% | $15.3B-18.2% | $18.7B+5.8% | $17.7B+10.2% | $16.0B-20.8% | $20.2B-12.3% | $23.1B+232.2% | $6.9B | N/A |
| Non-Current Liabilities | $32.1B-12.2% | $36.5B-5.3% | $38.6B-12.4% | $44.0B-18.3% | $53.9B-2.1% | $55.0B+0.6% | $54.7B+329.8% | $12.7B | N/A |
| Long-Term Debt | $26.5B-10.6% | $29.6B-2.8% | $30.5B-10.7% | $34.1B-18.2% | $41.7B-0.5% | $41.9B-2.7% | $43.1B+364.0% | $9.3B | N/A |
| Total Equity | $46.3B-3.8% | $48.1B+0.5% | $47.9B+2.3% | $46.8B+0.1% | $46.8B+6.5% | $43.9B-6.2% | $46.8B+148.9% | $18.8B+7.5% | $17.5B |
| Retained Earnings | $7.9B-13.9% | $9.2B-20.8% | $11.6B-4.7% | $12.2B-10.7% | $13.7B+7.1% | $12.7B-11.6% | $14.4B-1.7% | $14.7B | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
TAK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.1B+48.9% | $4.7B-35.6% | $7.4B-20.4% | $9.2B+1.2% | $9.1B+46.7% | $6.2B+109.9% | $3.0B-16.6% | $3.6B+51.7% | $2.3B |
| Depreciation & Amortization | $30.3M-39.0% | $49.7M+184.7% | $17.5M+343.1% | $3.9M-96.2% | $103.0M-78.1% | $471.2M+3516.8% | $13.0M-90.5% | $137.5M+348.4% | $30.7M |
| Capital Expenditures | $1.3B+15.5% | $1.2B+9.5% | $1.1B+4.4% | $1.0B+0.9% | $1.0B-14.9% | $1.2B+68.4% | $701.8M+11.2% | $630.9M+14.0% | $553.5M |
| Free Cash Flow | $5.7B+59.7% | $3.6B-43.2% | $6.3B-23.5% | $8.2B+1.2% | $8.1B+61.2% | $5.0B+122.7% | $2.3B-22.6% | $2.9B+63.3% | $1.8B |
| Investing Cash Flow | -$2.4Bn/m | -$3.1Bn/m | -$4.6Bn/m | -$1.6B-145.9% | $3.6B+31.0% | $2.7Bn/m | -$25.6Bn/m | -$878.9Mn/m | -$5.9B |
| Financing Cash Flow | -$5.0Bn/m | -$2.3Bn/m | -$5.3Bn/m | -$8.8Bn/m | -$9.8Bn/m | -$9.3B-135.1% | $26.6Bn/m | -$3.1B-218.1% | $2.6B |
| Dividends Paid | $2.0B+6.3% | $1.9B-9.8% | $2.1B-9.9% | $2.3B-8.8% | $2.6B-2.5% | $2.6B+103.5% | $1.3B-3.3% | $1.3B+5.1% | $1.3B |
| Share Buybacks | $346.4M+2113.0% | $15.7M-92.3% | $203.9M-68.8% | $654.2M+3279.8% | $19.4M-96.1% | $490.6M+4532.7% | $10.6M-97.3% | $391.2M+88.5% | $207.5M |
Not reported in any period shown, so not listed: Stock-Based Compensation.
TAK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.5%-1.0pp | 66.5%-2.6pp | 69.1%+0.1pp | 69.0%+0.1pp | 68.9%+2.0pp | 66.9%-2.0pp | 68.9%-3.1pp | 72.0%+4.2pp | 67.7% |
| Operating Margin | 7.5%+2.5pp | 5.0%-7.2pp | 12.2%-0.7pp | 12.9%-3.0pp | 15.9%+12.9pp | 3.0%-8.3pp | 11.3%-2.3pp | 13.7%+4.7pp | 9.0% |
| Net Margin | 2.4%-1.0pp | 3.4%-4.5pp | 7.9%+1.4pp | 6.5%-5.3pp | 11.8%+10.4pp | 1.3%-5.1pp | 6.5%-4.1pp | 10.6%+3.9pp | 6.6% |
| Return on Equity | 1.6%-0.4pp | 2.0%-3.0pp | 5.0%+0.9pp | 4.0%-3.2pp | 7.3%+6.3pp | 0.9%-1.7pp | 2.6%-6.8pp | 9.4%+3.5pp | 5.9% |
| Return on Assets | 0.8%-0.2pp | 0.9%-1.3pp | 2.3%+0.5pp | 1.8%-1.2pp | 2.9%+2.6pp | 0.4%-0.6pp | 1.0%-3.6pp | 4.5% | N/A |
| Current Ratio | 1.01-0.1x | 1.11+0.1x | 0.97-0.2x | 1.21-0.3x | 1.53+0.4x | 1.130.0x | 1.17-0.3x | 1.46 | N/A |
| Debt-to-Equity | 0.570.0x | 0.620.0x | 0.64-0.1x | 0.73-0.2x | 0.89-0.1x | 0.950.0x | 0.92+0.4x | 0.49 | N/A |
| Liabilities-to-Equity | 1.050.0x | 1.08-0.1x | 1.20-0.1x | 1.32-0.2x | 1.50-0.2x | 1.71+0.1x | 1.66+0.6x | 1.05 | N/A |
| Asset Turnover | 0.320.0x | 0.280.0x | 0.290.0x | 0.270.0x | 0.250.0x | 0.26+0.1x | 0.15-0.3x | 0.43 | N/A |
| FCF Margin | 18.7%+6.0pp | 12.7%-8.1pp | 20.8%-7.2pp | 28.0%-0.1pp | 28.1%+11.6pp | 16.5%+4.5pp | 12.0%-5.6pp | 17.6%+6.0pp | 11.5% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited TAK | FY2025 | $30.6B | $720.0M | 2.4% | $63.7B | 41/100 |
| Haleon plc HLN | FY2025 | $14.8B | $2.2B | 15.1% | $44.1B | 59/100 |
| ZOETIS INC. ZTS | FY2025 | $9.5B | $2.7B | 28.2% | $32.9B | 72/100 |
| Teva Pharmaceutical Industries Limited TEVA | FY2025 | $17.3B | $1.4B | 8.2% | $47.4B | 34/100 |
| United Therapeutics Corp UTHR | FY2025 | $3.2B | $1.3B | 41.9% | $24.2B | 88/100 |
| Dr. Reddy's Laboratories Limited RDY | FY2026 | $3.6B | $452.0M | 12.6% | $11.0B | 64/100 |
Where Takeda Pharmaceutical Company Limited Ranks
Frequently Asked Questions
What is Takeda Pharmaceutical Company Limited's annual revenue?
Takeda Pharmaceutical Company Limited (TAK) reported $30.6B in total revenue for fiscal year 2025. This represents a 8.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Takeda Pharmaceutical Company Limited's revenue growing?
Takeda Pharmaceutical Company Limited (TAK) revenue grew by 8.4% year-over-year, from $28.2B to $30.6B in fiscal year 2025.
Is Takeda Pharmaceutical Company Limited profitable?
Yes, Takeda Pharmaceutical Company Limited (TAK) reported a net income of $720.0M in fiscal year 2025, with a net profit margin of 2.4%.
What is Takeda Pharmaceutical Company Limited's EBITDA?
Takeda Pharmaceutical Company Limited (TAK) had EBITDA of $2.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Takeda Pharmaceutical Company Limited have?
As of fiscal year 2025, Takeda Pharmaceutical Company Limited (TAK) had $2.6B in cash and equivalents against $26.5B in long-term debt.
What is Takeda Pharmaceutical Company Limited's gross margin?
Takeda Pharmaceutical Company Limited (TAK) had a gross margin of 65.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Takeda Pharmaceutical Company Limited's operating margin?
Takeda Pharmaceutical Company Limited (TAK) had an operating margin of 7.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Takeda Pharmaceutical Company Limited's net profit margin?
Takeda Pharmaceutical Company Limited (TAK) had a net profit margin of 2.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Takeda Pharmaceutical Company Limited's return on equity (ROE)?
Takeda Pharmaceutical Company Limited (TAK) has a return on equity of 1.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Takeda Pharmaceutical Company Limited's free cash flow?
Takeda Pharmaceutical Company Limited (TAK) generated $5.7B in free cash flow during fiscal year 2025. This represents a 59.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Takeda Pharmaceutical Company Limited's operating cash flow?
Takeda Pharmaceutical Company Limited (TAK) generated $7.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Takeda Pharmaceutical Company Limited's total assets?
Takeda Pharmaceutical Company Limited (TAK) had $95.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Takeda Pharmaceutical Company Limited's capital expenditures?
Takeda Pharmaceutical Company Limited (TAK) invested $1.3B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Takeda Pharmaceutical Company Limited spend on research and development?
Takeda Pharmaceutical Company Limited (TAK) invested $4.9B in research and development during fiscal year 2025.
What is Takeda Pharmaceutical Company Limited's current ratio?
Takeda Pharmaceutical Company Limited (TAK) had a current ratio of 1.01 as of fiscal year 2025, which is considered adequate.
What is Takeda Pharmaceutical Company Limited's debt-to-equity ratio?
Takeda Pharmaceutical Company Limited (TAK) had a debt-to-equity ratio of 0.57 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Takeda Pharmaceutical Company Limited's liabilities-to-equity ratio?
Takeda Pharmaceutical Company Limited (TAK) had a liabilities-to-equity ratio of 1.05 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Takeda Pharmaceutical Company Limited's return on assets (ROA)?
Takeda Pharmaceutical Company Limited (TAK) had a return on assets of 0.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Takeda Pharmaceutical Company Limited's P/E ratio?
Takeda Pharmaceutical Company Limited (TAK) trades at 88.4x earnings, its market capitalization divided by $720.0M net income, FY2025. The market capitalization is $63.7B as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Takeda Pharmaceutical Company Limited's price-to-sales ratio?
Takeda Pharmaceutical Company Limited (TAK) trades at 2.1x sales, its market capitalization divided by $30.6B revenue, FY2025. The market capitalization is $63.7B as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Takeda Pharmaceutical Company Limited's Altman Z-Score?
Takeda Pharmaceutical Company Limited (TAK) has an Altman Z-Score of 1.30, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Takeda Pharmaceutical Company Limited's Piotroski F-Score?
Takeda Pharmaceutical Company Limited (TAK) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Takeda Pharmaceutical Company Limited's earnings high quality?
Takeda Pharmaceutical Company Limited (TAK) has an earnings quality ratio of 9.80x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Takeda Pharmaceutical Company Limited cover its interest payments?
Takeda Pharmaceutical Company Limited (TAK) has an interest coverage ratio of 2.49x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited (TAK) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.